Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Narrative (Details)

v3.19.3.a.u2
Revenue Recognition - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment 2  
Increase in pharma contract liabilities $ 0.2  
Increase in pharma contract liabilities (as a percent) 8.00%  
Pharma contract liability, revenue recognized $ 2.2  
Amortization of contract commissions $ 1.2 $ 1.0